Form 4: IN8BIO COO Kate Rochlin Granted 80,000 Stock Options

IN8BIO's President and COO, Kate Rochlin, was granted 80,000 employee stock options with an exercise price of $1.96, vesting over four years.

Summary

• Kate Rochlin, President and COO of IN8BIO, INC. (INAB), acquired 80,000 employee stock options.
• The options have an exercise price of $1.96 per share.
• The grant date for these options was February 4, 2026.
• The options will vest with 25% of the shares on February 4, 2027, and the remaining shares vesting in thirty-six equal monthly installments thereafter.
• The options have an expiration date of February 4, 2036.
• Following this transaction, Kate Rochlin beneficially owns 80,000 derivative securities (employee stock options).

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive event. While a routine compensation matter, it signifies continued executive commitment and aligns management's financial incentives with shareholder value, which is generally favorable.

Positives

• The grant of stock options aligns the interests of President and COO Kate Rochlin with those of shareholders, incentivizing long-term company performance.
• The vesting schedule encourages continued service and commitment from a key executive.

Future Outlook

The grant of stock options is a forward-looking incentive designed to motivate the President and COO to contribute to the company's long-term growth and shareholder value creation, with vesting tied to continued service.

Industry Context

StockSavvy.ai notes that granting stock options to key executives like the President and COO is a standard practice across the biotechnology and pharmaceutical industries. This compensation structure is widely used to attract, retain, and incentivize top talent by linking their personal financial success to the company's stock performance, thereby aligning executive interests with those of shareholders.

Comparison to Industry Standards

• Executive stock option grants are a common component of compensation packages in growth-oriented sectors like biotechnology, similar to practices observed at companies such as Moderna, BioNTech, or Regeneron Pharmaceuticals, where long-term incentives are crucial for retaining leadership in R&D-intensive environments.
• The vesting schedule, with an initial cliff followed by monthly installments, is a typical structure designed to ensure executive retention and sustained performance over several years, consistent with industry benchmarks for executive equity awards.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: The grant of options aligns executive interests with shareholder value creation, potentially leading to better long-term performance.
• Employees: This transaction highlights the company's use of equity-based compensation to attract and retain key talent, which can be a positive signal for other employees.

Next Steps

• The options will begin vesting on February 4, 2027, with 25% of the shares, followed by 36 equal monthly installments.
• Kate Rochlin will continue to provide service to IN8BIO, INC. to fulfill the vesting conditions.

Key Dates

Keywords

IN8BIO, INAB, Stock Options, Executive Compensation, Insider Transaction, Form 4, Kate Rochlin, Employee Stock Option, Vesting